GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Incyte Corporation
Massachusetts General Hospital
Thomas Jefferson University
M.D. Anderson Cancer Center
Thomas Jefferson University
Hangzhou Sumgen Biotech Co., Ltd.
Fred Hutchinson Cancer Center
Takeda
OHSU Knight Cancer Institute
Prelude Therapeutics
Bellicum Pharmaceuticals
AstraZeneca
Rutgers, The State University of New Jersey
Fred Hutchinson Cancer Center
Molecular Templates, Inc.
Kiadis Pharma
University of California, San Diego
Kiadis Pharma
Novartis
M.D. Anderson Cancer Center
Novartis
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
University of Arizona
St. Jude Children's Research Hospital
Centre Antoine Lacassagne
Celgene
University Health Network, Toronto
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Virginia
Gilead Sciences
University of California, San Francisco
University of California, San Francisco
Nevada Cancer Institute